CG Oncology, Inc. (CGON) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
CGON currently has 76.7M outstanding shares. with moderate dilution risk from 27.6M authorized shares representing 35.9% potential dilution. The company has diluted shareholders by 15.55% over the past 2 years through share issuances.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Nov 14, 2025 |
10-Q filing | 76.7M shares outstanding |
77M | 28M |
| Aug 08, 2025 |
10-Q filing | 76.2M shares outstanding |
76M | 28M |
| May 13, 2025 |
10-Q filing | 76.2M shares outstanding |
76M | 28M |
| Mar 28, 2025 |
10-K filing | 76.2M shares outstanding |
76M | 28M |
| Dec 11, 2024 |
S-1/A filing: This is an S-1/A filing. The document discusses indemnification agreements with directors and officers, recent sales of unregistered securities including Series E and F redeemable convertible preferred stock, and grants of stock options. |
67M | 28M |
| Dec 11, 2024 |
S-1 filing: The company is offering 7,300,000 shares of common stock, and a selling stockholder is offering an additional 700,000 shares of common stock. |
68M | 28M |
| Nov 12, 2024 |
10-Q filing | 67.1M shares outstanding |
67M | 20M |
| Aug 08, 2024 |
10-Q filing | 66.6M shares outstanding |
67M | 20M |
| May 09, 2024 |
10-Q filing | 66.6M shares outstanding |
67M | 20M |
| Jan 23, 2024 |
S-1/A filing: This is an S-1/A filing for a common stock offering underwritten by Morgan Stanley, Goldman Sachs & Co. LLC, Cantor, and LifeSci Capital. The offering includes 17,000,000 shares of common stock and an underwriter's over-allotment option of 2,550,000 shares, with a proposed IPO price of $17.00 per share. The company intends to use the net proceeds to fund research and development and for working capital and other general corporate purposes. |
43M | 20M |
| Jan 18, 2024 |
S-1/A filing: This is an S-1/A filing for an offering of common stock with Morgan Stanley, Goldman Sachs & Co. LLC, Cantor, and LifeSci Capital as underwriters. The company proposes to offer 11,800,000 shares of common stock and an underwriter's option of 1,770,000 shares. |
43M | 14M |
| Jan 02, 2024 |
S-1 filing: S-1 filing for an offering of common stock with Morgan Stanley, Goldman Sachs & Co. LLC, Cantor, and LifeSci Capital as underwriters. |
410M | 0 |